score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C						Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		34		
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.S884*						Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S884* (Nonsense)		34		
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.I767M						Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.I767M (Missense)		34		
Investigate Actionability	Preclinical			Copy Number	CDKN2A	Deletion							Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214																	CDKN2A Deletion		34		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H													Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		34		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.M965fs*13						Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.M965fs*13 (Frameshift)		34		
